Contemporary Insights into Painful Diabetic Neuropathy and Treatment with Spinal Cord Stimulation
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
A substantial body of literature is available on the natural history of diabetes, but much less is understood of the natural history of painful diabetic peripheral neuropathy (PDPN), a pervasive and costly complication of diabetes mellitus. Multiple mechanisms have been proposed, including polyol pathway activation, advanced glycosylation end-product formation, and vasculopathic changes. Nevertheless, specific treatment modalities addressing these basic issues are still lacking. The mainstay of treatment includes pharmacological management with antidepressants, anticonvulsants, and opioids, but these drugs are often limited by unfavorable side-effect profiles. For over 30 years, spinal cord stimulation (SCS) has been used extensively for the management of various chronic neuropathic pain states. In the past decade, interest in the use of SCS for treatment of PDPN has increased. This article reviews pathophysiological mechanisms of PDPN, proposed mechanisms of SCS, and the role of SCS for the treatment of PDPN.
- Wild S, Roglic G, Green A, et al. Global prevalence of diabetes estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27:1047–53. CrossRef
- Zhao Y, Ye W, Boye KS, et al. Healthcare charges and utilization associated with diabetic neuropathy: impact of Type 1 diabetes and presence of other diabetes-related complications and comorbidities. Diabet Med. 2009;26:61–9. CrossRef
- • American Diabetes Association: Economic cost of diabetes in the U.S. in 2007. Diabetes Care 2008;31:596–615. This article provides a very comprehensive overview of the cost of care for diabetes and diabetes-related comorbidities throughout the entire continuum of the health care system.
- Daousi C, Benbow SJ, Woodward A, et al. The natural history of chronic painful diabetic neuropathy in a community diabetes population. Diabet Med. 2006;23:1021–4. CrossRef
- Boulton AJ, Drury J, Clarke B, et al. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care. 1982;5:386–90. CrossRef
- Oyibo SO, Prasad YD, Jackson NJ, et al. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy: a pilot study. Diabet Med. 2002;19:870–3. CrossRef
- Podwall D, Gooch C. Diabetic neuropathy: clinical features, etiology and therapy. Curr Neurol Neurosci Rep. 2004;4:55–61. CrossRef
- Oates PJ. Polyol pathway and diabetic peripheral neuropathy. Int Rev Neurobiol. 2002;50:325–66. CrossRef
- Kihara M, Mitsui Y, Shioyama M, et al. Effect of zenarestst, an aldose reductase inhibitor, on endoneurial blood flow in experimental diabetic neuropathy of rat. Neurosci Lett. 2001;310:81–4. CrossRef
- Krendal DA: Diabetic neuropathies. In Neuromuscular Function and Disease: Basic Clinical and Electrodiagnositc Aspects. Edited by Brown WE, Bolton CE, Aminoff MD. Philadelphia: WB Suanders; 2002:1061–80.
- The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetic therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122:561–8.
- Thomalley PJ. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol. 2002;50:37–50. CrossRef
- Cameron NE, Eaton S, Cotter MA, et al. Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia. 2001;44:1973–88. CrossRef
- Hall KE, Liu J, Sima AA, et al. Impaired inhibitory G-protein function contributes to increased calcium currents in rats with diabetic neuropathy. J Neurophysiol. 2001;86:760–70.
- Shah BS, Gonzales MI, Bramwell S, et al. β3, a novel auxiliary subunit for the voltage gated sodium channel is upregulated in sensory neurones following streptozocin induced diabetic neuropathy in rat. Neurosci Lett. 2001;309:1–4. CrossRef
- Novella SP, Inzucchi SE, Goldstein JM, et al. The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. Muscle Nerve. 2001;24:1229–31. CrossRef
- Summer CJ, Sheth S, Griffith JW, et al. The spectrum of neuropathy in diabetes and glucose tolerance. Neurology. 2003;60:108–11.
- Partanen J, Niskansen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin dependent diabetes mellitus. N Engl J Med. 1995;333:89–94. CrossRef
- Polydefkis M, Hauer P, Griffin JW, et al. Skin biopsy as a tool to assess distal small fiber innervations in diabetic neuropathy. Diabetes Technol Ther. 2001;3:23–8. CrossRef
- • Kilpatrick ES, Rigby AS, Atkin SL: The Diabetic Control and Complications Trial: the gift that keeps giving. Nat Rev Endocrinol 2009;5:537–45. This thorough review of the background and data to date of the Diabetic Control and Complications Trial provides valuable data from a cohort studied for over a quarter of a century, with detailed information on relationship of glycemic control and the entire spectrum of diabetic complications.
- Hurley RW, Lesley MR, Adams MC, Brummett CM, Wu CL. Pregabalin as a treatment for painful diabetic peripheral neuropathy: a meta-analysis. Reg Anesth Pain Med. 2008;33:389–94.
- • Ziegler D: Painful diabetic neuropathy: advantage of novel drugs over old drugs? Diabetes Care 2009;32 Suppl 2:S414-9. This is an excellent review of the pharmacological therapeutic options for the treatment of PDPN. Detailed information on the numbers needed to treat and harm allows for data-driven therapy for PDPN.
- Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324–34. CrossRef
- Ziegler D, Nowak H, Kempler P, et al. Treatment of symptomatic diabetic polyneuropathy with the anti-oxidant α-lipoic acid: a meta-analysis. Diabet Med. 2004;21:114–21. CrossRef
- Zeigler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29:2365–70. CrossRef
- Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965;150:971–9. CrossRef
- El-Khoury C, Hawwa M, Baliki M, et al. Attenuation of neuropathic pain by segmental and supraspinal activation of the dorsal column system in awake rats. Neuroscience. 2002;112:541–53. CrossRef
- • Wu M, Linderoth B, Foreman RD: Putative mechanism behind effects of spinal cord stimulation on vascular diseases: a review of experimental studies. Auton Neurosci 2008;138:9–23. This is an excellent article to read for a clear understanding of the effects of SCS on the CVS through the sympathetic system. Diagrams and layout allow for a clear understanding of the science.
- Croom JE, Foreman RD, Chandler MJ, et al. Cutaneous vasodilatation during dorsal column stimulation is mediated by dorsal roots and CGRP. Am J Physiol. 1997;272:H950–7.
- Goksel HM, Karadag O, Turaclar U, et al. Nitric oxide synthetase inhibition attenuates vasoactive response to spinal cord stimulation in an experimental model. Acta Neurochir (Wien). 2001;143:383–90. CrossRef
- Wu M, Komori N, Qin C, et al. Sensory fibers containing vanilliod receptor-1 (VR-1) mediate spinal cord stimulation-induced vasodilatation. Brain Res. 2006;1107:177–84. CrossRef
- Wu M, Komori N, Qin C, et al. Extracellular signal regulated kinase (ERK) and protein kinase B (AKT) pathways involved in spinal cord stimulation (SCS)-induced vasodilatation. Brain Res. 2008;207:73–83. CrossRef
- • Prager JP: What does the mechanism of spinal cord stimulation tell us about complex regional pain syndrome? Pain Med 2010;11:1278–83. This is an excellent review of how the mechanism of action of SCS informs the understanding of the neuropathic pain conditions, complex regional pain syndrome in particular.
- Stiller CO, Cui JG, O’Connor WT, et al. Release of gamma-aminobutyric acid in the dorsal horn and the suppression of tactile allodynia by spinal cord stimulation in mononeuropathic rats. Neurosurgery. 1996;39:367–74. CrossRef
- Schectmann G, Song Z, Ulitenius C, et al. Cholinergic mechanisms involved in pain relieving effect of spinal cord stimulation in a model of neuropathy. Pain. 2008;139:136–45. CrossRef
- Linderoth B, Stiller CO, Gunasekera L, et al. Gamma-aminobutyric acid is released in the dorsal horn by electrical spinal cord stimulation: an in vivo microdialysis study in the rat. Neurosurgery. 1994;34:484–8. CrossRef
- Tesfaye S, Watt J, Benbow SJ, et al. Electrical spinal-cord stimulation for painful diabetic peripheral neuropathy. Lancet. 1996;348:1698–701. CrossRef
- Daousi C, Benbow SJ, MacFarlane IA. Electrical stimulation in the long-term treatment of chronic painful diabetic neuropathy. Diabet Med. 2005;22:393–8. CrossRef
- de Vos CC, Rajan V, Steenbergen W, et al. Effect and safety of spinal cord stimulation for the treatment of chronic pain caused by diabetic neuropathy. J Diabetes Complications. 2009;23:40–5. CrossRef
- Kapural L, Hayek S, Stanton-Hicks M, et al. Decreased insulin requirements with spinal cord stimulation in a patient with diabetes. Anesth Analg. 2004;98:745–6. CrossRef
- Jeon JY, Weiss CB, Steadward RD, et al. Improved glucose tolerance and insulin sensitivity after electrical stimulation-assisted cycling in people with spinal cord injury. Spinal Cord. 2002;40:110–7. CrossRef
- Contemporary Insights into Painful Diabetic Neuropathy and Treatment with Spinal Cord Stimulation
Current Pain and Headache Reports
Volume 16, Issue 1 , pp 43-49
- Cover Date
- Print ISSN
- Online ISSN
- Current Science Inc.
- Additional Links
- Diabetic neuropathy
- Spinal cord stimulation
- Anesthetic techniques
- Pain management
- Industry Sectors